Orchid Pharma Releases Q4 FY26 Earnings Call Transcript
Orchid Pharma's Q4 FY26 standalone revenue was INR 238 crore, with EBITDA at INR 42.3 crore. Full-year FY26 revenue was INR 811 crore and EBITDA INR 101 crore. The company sees stabilization in the Cephalosporin industry and is building an anti-infectives platform. Merger with Dhanuka Labs is pending. 7ACA project commissioning by Q1 2027.
The announcement provides a comprehensive update on financial performance, strategic initiatives like mergers and new projects (7ACA, Exblifep, Cefiderocol), and future market development, particularly in the US. These details are material for investors and stakeholders in assessing the company's trajectory.
The announcement is a transcript of an earnings call, which provides detailed financial performance and strategic updates. While the company indicates stabilization and future growth plans, the financial performance for the full year shows a decline compared to the previous year. The tone is cautiously optimistic.
Orchid Pharma Limited has released the transcript of its Analysts/Investors Earning Call held on May 26, 2026. The call focused on the financial performance for Quarter-IV and the full Financial Year 2025-26, which ended on March 31, 2026. The company reported standalone revenue for Q4 FY26 at approximately INR 238 crores, showing stability compared to INR 237 crores in Q4 FY25. EBITDA for Q4 stood at approximately INR 42.3 crores. For the full financial year '26, standalone revenue was INR 811 crores, down from INR 922 crores in FY '25, with EBITDA at INR 101 crores compared to INR 155 crores in FY '25. Management indicated that the worst phase of the pricing cycle in the Cephalosporin industry may be behind them, with early signs of recovery and stabilization observed in Q4. The company is strategically building a differentiated anti-infectives platform, including innovation, APIs, FDFs, and antimicrobial stewardship capabilities. The merger between Dhanuka Laboratories and Orchid Pharma is awaiting a formal written order, with expected synergies contributing to EBITDA margin expansion. The 7ACA project is on track for commissioning in Q1 calendar year 2027. Exblifep is in early commercialization in India and Europe, with ongoing discussions for markets like the United States, Russia, Latin America, and Southeast Asia. The Cefiderocol facility is expected to be commissioned by the end of 2026, with product launch anticipated in Q2 or Q3 calendar year 2027. Orchid Pharma is also investing in fill, finish, and formulation capabilities to address regulated sterile formulation opportunities for the U.S. market, targeting an opportunity size of approximately $1.2 billion. The company expects the U.S. business to become a significant contributor to its top and bottom line over the next five years. Discussions for Enmetazobactam out-licensing are in advanced stages, with hopes of announcing a deal within the current quarter.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.